Child's Adipose Cells: Capacity of Tissue Regeneration (cicASChild)
Evaluation of Tissue Regeneration Potential (in the Skin) of Child's Adipose Cells During the Development.
調査の概要
詳細な説明
Through this study, the medium term objective is to approach a clinical protocol for treatment of pathological scars in developing an appropriate way to deliver ADSC for a future clinical application, while ensuring the safety of such procedure.
The primary goal of this work is to determine whether ADSC from children prepared according to Good Manufacturing Practice (GMP), is associated with an improvement of wound healing in vivo as demonstrated with adult ADSC. To answer this question, 40 samples of adipose tissue of children obtained from settled surgery (inguinal hernia and vesico-ureteral reflux by suprapubic way) will be performed within the 2 groups of children; 0 to 1 year and 2 to 13 years, defined from data acquired in the previous protocol. Wound healing will be evaluated in a nude mouse model of skin burn. A macroscopic analysis will be carried out with two indexes described in the literature (re-epithelialization and scar contraction) and expressed as a percentage of the initial lesion at different times (3 days, 7 days, 10 days, 14 days, 21 days, 30 days). A microscopic analysis will be conducted to determine the rate of re-epithelialization (day 7) and the evolution of the skin structural parameters (dermal and epidermal thickness, density of collagen, inflammatory infiltration). These indexes will be defined in the treated group (burned mice and injected with pediatric ADSC) from control mice (burned but not injected with cells). A comparative analysis between the two groups of age will be conducted that will be also compared to data collected with adult ADSC.
To answer to the second part of this primary goal regarding to safety, the study will perform a long-term follow-up (1 yr) of burned mice injected with of ADSC, to obtain data in the animal after transplantation of cells and for further clinical study.
Complementary in vitro investigations still seems necessary to better understand the specificities of ADSC from pediatric origin and particularly to perform transcriptomic and epigenetic studies.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Toulouse、フランス、31059
- CHU de Toulouse-Purpan
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
INCLUSION CRITERIA:
- absence of tumor pathology, known systemic or chronic viral
- absence of long-term treatment
signing informed consent form of persons exercising parental authority
1st group (20 children):
- Between 0 and less than or equal to 1 year
- Weighing at least 1500 g at birth
Age ≥ 37 weeks of amenorrhea
2nd group (20 children)
- Older than 1 year to 10 years
EXCLUSION CRITERIA:
- Children whose age is above 10 years
- premature babies with birth weight under 1500 grams
- Any child with a tumor pathology, a systemic disease, or whose serology (viral) would be known as positive (HIV 1 and 2, hepatitis B, C, ...).
- Any child following a long term treatment.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：基礎科学
- 割り当て：非ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の：0-1 year old child
Adipose tissue sample in 0-1 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
|
adipose tissue sample
|
|
他の：>1-10 year old child
Adipose tissue sample in >1-10 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
|
adipose tissue sample
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Efficacity of treatment as assessed by surface healed skin (cm2) in animal model
時間枠：1 month after injection
|
Efficacy of ADSC in animal model healing
|
1 month after injection
|
|
Efficacity of treatment as assessed by surface healed skin (cm2) in animal model
時間枠：1 year after injection
|
Efficacy of ADSC in animal model healing
|
1 year after injection
|
|
Security as assessed by absence of tumorigenicity at injection site in animal model
時間枠：1 month after injection
|
Clinical security of treatment
|
1 month after injection
|
|
Security as assessed by absence of tumorigenicity at injection site in animal model
時間枠：1 year after injection
|
Clinical security of treatment
|
1 year after injection
|
協力者と研究者
捜査官
- 主任研究者：Philippe GALINIER, MD, PhD、Chirurgie pédiatrique - Hôpital des enfants
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
adipose tissue sampleの臨床試験
-
Assistance Publique Hopitaux De Marseilleまだ募集していません
-
Aarhus University HospitalNovo Nordisk A/S; University of Aarhus; LifeCell完了